Prolight Diagnostics’ collaboration with G&H | ITL propels development
Prolight Diagnostics have appointed G&H | ITL for the development of its innovative point-of-care system, Psyros. The development project started in early 2023 and...
Abliva’s mission to become mitochondrial medicine powerhouse
Abliva’s CMO Magnus Hansson attended the 8th annual meeting of Mitochondrial Medicine – Therapeutic Development in March. The conference brings together leaders in translational...
Prolight’s COO comments on partnership with FlexMedical Solutions
Prolight Diagnostics has appointed FlexMedical Solutions as contract manufacturing partner for the disposable cartridge in the Psyros point-of-care system. Prolight's COO, Karl Bullen, has...
Chordate comments on Q4 and case report
Chordate Medical has published the year-end report for 2023, which showed an increase in sales compared to the previous year. The company has also...
Lipum seeks patent protecting inflammation-driven cancer treatment
Lipum has submitted an international patent application for SOL-116 as a treatment for inflammation-driven cancer. The patent application is based on the company's research...
Synact focuses on pushing forward rheumatoid arthritis project
SynAct Pharma is intent on making a turnaround after posting disappointing study results with lead asset resomelagon. The Swedish biotech is conducting a directed...
Alligator Bioscience on the importance of prolonging life
What does time mean to a person who's cancer might not be cured? Prolonged life can bring hope for alternative treatments, or simply allow...
Cyxone comments on the clinical collaboration in the UK
Cyxone has entered into a research collaboration with a renowned British research group in Glasgow with the aim of conducting an exploratory phase II...
Monthly of Sweden CEO talks launches, growth, and capital acquisition
MonthlyCup started up in 2015 and is now a prominent player in the menstrual cup market. The company is currently expanding its product offerings,...
Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”
Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of next-generation radioconjugates to treat cancer....